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ORTHOCLONE OKT3 was shown, in a randomized multicenter 
trial for acute rejection of cadaveric renal transplants, 
to reverse 94 percent of the rej ecti ons as contrasted with 
a 75 percent reversal rate obtained with conventional 
steroid treatment (P=O.009). Thi s superi or reversal rate 
wi th OKT3 was refl ected in an improved one-year graft 
survival rate (62 percent) as compared with the 
steroid-treated group (45 percent). We now present the 
results of a clinical trial involving 173 patients with 
acute renal allograft rejection that failed to respond to 
conventional immunosuppressive therapies. OKT3 rilonoclonal 
anti body was gi ven for a 10-14 day course and the dosage 
of other immunosuppressive drugs was reduced. Acute 
rejection was reversed by OKT3 monoclonal antibody in 121 
patients (70 percent) and actuarial graft survival at 6 
months was 52 percent. The therapeutic properties of OKT3 
are ascribed to blocking of the T3-antigen-receptor 
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complex of T lymphocytes and consequent blocking of 
cytotoxic T lymphocyte rejection of the allograft. 
INTRODUCTION 
Transpl antation of renal all ografts is the preferred 
treatment for many patients with tenninal renal failure. 
Immunological rejection is abated by HLA matching of donor 
and patient and by immunosuppressive agents, notably 
corticosteroids, azathioprine, polyclonal anti-thymocyte 
globulin and lately cyclosporine, but rejection episodes 
still occur in a majority of patients. Rejection episodes 
are conventi onally treated wi th high-dose steroi d pul ses 
(Glass et. al., 1983) or with anti-thymocyte globulin 
(Shield et. al., 1979). 
T cells, which are involved in cellular rejection of 
allografts, recognize the "foreign" nature of the graft by 
antigen recognition structures in the cell surface (Mak 
and Yanagi, 1984). The antigen recognition structure is a 
disulfide-linked heterodimer which consists of two 
glycosylated polypeptide chains. OKT3 recognizes one of 
three associated polypeptide chains that comprise the T3 
complex (Kung et. al., 1979; van den Elsen et. al., 
1984). The T3 complex transmits an intracellular Signal 
after the T cell has recognized antigen (Imboden et. al., 
1985; Reinherz et. al., 1982). Binding of OKT3 to the T3 
component on the T cell surface blocks T cell function in 
vitro (Chang et. al., 1981) and also in vivo, as tne 
efficacy of OKT3 in reversing the acute rejection of renal 
transplants testifies (Goldstein et. al., 1985). 
We have previously reported that the monoclonal 
antibody OKT3 is effective in the treatment of acute 
rejection of renal allografts (Goldstein et. al., 1985). 
In this study, 123 patients undergoing acute rejection of 
cadaveric renal transplants were treated with either OKT3 
5 mg i.v. daily for a mean period of 14 days, with 
concomitant lowering of azathioprine and prednisone (63 
patients), or with conventional high-dose steroid therapy 
(60 patients). Simil ar immunosuppressi ve mai ntenance 
therapies of azathioprine and prednisone were subsequently 
administered to both groups and recurrent episodes of 
rejection were similarly treated with high-dose steroids 
or anti-thymocyte globulin. The results of the study 
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showed a superior efficacy of reversal of rejection by 
OKT3 (94 percent) which was significantly higher (P=O.009) 
than that achieved with conventional steroid treatment (75 
percent) • 
A second rejection was common to both groups, 66 
percent of patients initially treated with OKT3 and 73 
percent in patients treated with conventional steroids. 
Subsequent kidney loss due to repeated rejection was a1 so 
similar in both groups, 33 percent and 38 percent for OKT3 
therapy and conventional steroid therapy, respectively. 
However, based on the superior reversal rate obtained with 
OKT3 therapy, at one year the OKT3 treated group 
demonstrated an improved graft survival rate (62 percent) 
as contrasted to the steroid treated group (45 percent). 
We report here on the successful use of OKT3 in 
patients with acute renal allograft rejection that failed 
to respond to conventional therapy. 
METHODS 
Production of OKT3 
The OKT3-producing hybridoma, characterization of the 
OKT3 IgG2a antibody and its preparation as a sterile 
pyrogen-free formu1 ati on for parenteral dosage by wei ght 
of immunoglobulin, have been reported (Goldstein et. al., 
1985; Kung et. al., 1979). 
Eligibility Criteria 
The diagnosis of acute renal allograft rejection and 
reversal of rejection were based on the usual criteria of 
failing renal function and inflammation of the graft 
(Shi el d et. a1., 1979). In each case it was requi red that 
by these cri teri a the rejecti on epi sode was not respondi ng 
to conventi onally adequate courses of high-dose steroi d 
pulses and anti-thymocyte globulin, or that either of 
these agents was contraindicated or unavailable; reasons 
for contraindication included chronic infections or severe 
diabetes mellitus for steroids and hypersensitivity or 
adverse reacti ons for anti -thymocyte gl obu1 i n. Eacll 
patient was informed of the investigational status of OKT3 
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and signed a consent fonn. Use of OKT3 in each 
participating center was approved by ,an Institutional 
Review Board. 
OKT3 Treatment Regimen 
5 mg OKT3 was gi ven daily by intravenous push for 
10-14 days. Other immunosuppressive drugs were reduced in 
dosage during this period, with resumption to maintenance 
levels thereafter. During early studies with OKT3 five 
renal rejection patients (including two in the present 
study) developed severe pulmonary edema following the 
first injection of OKT3; all five patients had 
pre-existing fluid overload. After this association was 
recognized, as a precaution against fluid overload, OKT3 
therapy was i ni ti ated only ~fhen chest X-rays were deemed 
satisfactory and when no more than 3 percent gain in body 
weight was observed during the preceding week, in addition 
to a satisfactory overall clinical assessment. A bolus 
injection of 500 mg methylprednisolone or 1 gm 
hydrocortisone was given 1-6 h before the first injection 
of OKT3 to alleviate chills and fever that may accompany 
the first dose. 
Evaluation 
The status of the ki dney graft and the conditi on of 
the patient were formally evaluated at the conclusion of 
OKT3 therapy and six months later. Actuarial survivals 
were detennined by life table analysis (Gross and Clark, 
1975). 
RESULTS 
The 173 patients reported comprised 115 males and 58 
females, ranging in age from 2 to 65 (median 33) years, of 
whom 31 patients had diabetes mellitus. 140 patients were 
rejecting a first renal allograft, 28 a second, 4 a third 
and 1 a fourth renal allograft. 130 patients were 
rejecting grafts from cadavers and 43 were rejecting 
grafts from living donors, 42 related and one unrelated. 
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The pati ents recei ved treatment at 33 centers. 29 in 
the U.S.A., 2 in France, 1 in Italy, and 1 in South 
Afri ca. The immunosuppressi ve regimens in use at the tilile 
that graft rejection was recognized clinically included 
azathioprine plus prednisone (69 patients), azathioprine, 
prednisone and anti-thymocyte globulin, (16 patients), 
cyclosporine and prednisone (50 patients) and 
cyclosporine, azathi oprine, and predni sone (30 patients). 
Eight patients had a combination of i"~unosuppressive 
treatments combining the above regimens. After diagnosis 
of acute renal allograft rejection 66 patients were 
unsuccessfully treated with high dose steroid pulses and 
anti -thymocyte gl obul in for 24 ± 3 days (mean ± SEM) 
before OKT3 was initiated, 100 patients were 
unsuccessfully treated with high dose steroid pulses alone 
for 10 ± 1 days and 7 patients were unsuccessfully treated 
with anti-thymocyte globulin for 17 ± 7 days before 
initiation with OKT3 treatment (Table 1). 
TABLE 1. OKT3 Monoclonal Antibody Reversal of Acute Renal 
Allograft Rejection in Patients that Could not 
be Reversed by Conventional Treatments 
Failed treatment for Oats from first ~ejection Reversd 1 
current rejectIon treatement to fIrst JRT3 incidence (eercent) 
;nean t SEM 
Increased steroids and 24 • 3 49/66 (74 ) 
dnti-thymocyte globulin 
Increased steroids 10 • 67 !lOa 
( 67) 
Anti-thymocyte globulin 17 • 7 5/7 ( 711 
15 • 1 121/173 ( 70) 
Adverse Reactions and Patient Survival 
Flu-like symptoms occurred, mainly after the first 
dose of OKT3. On the first day these comprised pyrexia 
and chi 11 s (38 percent of cases), headache (20 percent), 
vomi ti ng or di arrhea (10-12 percent). On the second day, 
the incidence of these symptoms was reduced: pyrexia and 
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chills (15-28 percent), headache (14 percent) and nausea, 
diarrhea or vomiting (10-13 percent). During the 
remaining days of OKT3 treatment only pyrexia (18 percent) 
persisted in an incidence greater than 10 percent. 
Two patients developed severe pulmonary edema after 
the first injection of OKT3 and these patients, with 
pre-existing fluid overload, were among the first 33 
patients treated, during which period no special 
precautions were taken with respect to fluid overload. No 
cases of severe pulmonary edema occurred among the 
remaining 140 patients screened as above for fluid 
overload prior to the first injection of OKT3. 
168 of the patients (97 percent) survived to the time 
of analysis with 84 patients observed for at least 6 
months. No deaths were directly related to OKT3 therapy. 
Actuarial patient survival at 6 months was 95 percent. 
Reversal of Rejection 
Reversal rates are given in Table 1. Rejection was 
reversed by OKT3 in 70 percent of patients and resul ts 
were similar regardless of which conventional treatment 
regimens had been unsuccessfully used prior to OKT3 
therapy. 
Kidney Graft Survival 
Fi gure 1 is based on ki dney graft survi va 1 from time 
of first treatment with OKT3, according to life table 
analysi s, and si gnifies an actuarial 6-month graft 
survival of 52 percent, all deaths being considered as 
losses of ki dney functi on regardless of the status of the 
graft at the time of death. 
DISCUSSION 
Treatment with OKT3, coupled with reduction of 
preceding immunosuppressive medication, has been shown in 
a previ ous randomi zed study to be superi or to hi gh dose 
steroid pulses in reversing acute renal allograft 
rejection (Goldstein et. al., 1985). The use of OKT3 as 
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Fi gure 1. Life tabl e analysi s of ki dney graft survi val in 
patients treated with OKT3 for acute renal allograft 
rejection unresponsive to conventional immunosuppressive 
treatments. Numbers of patients with functioning kidney 
grafts bei ng foll owed at indicated time poi nts are 
indicated in parenthesis. 
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the sale immunosuppressive agent has also been explored in 
a preliminary open study for the prevention of acute renal 
allograft rejection, with administration from the time of 
transplantation (Kreis et. al., 1985). An initial 
protocol was di sconti nued after a bri ef period of time 
because all patients in the OKT3-treated group experienced 
acute rejection epi sodes at the end of the OKT3 treatlilent 
period, necessitating the introduction of steroids about 
12 days posttransplant. Evaluation of thi s prel imi nary 
study led to the conclusion that OKT3, albeit a major 
immunosuppressive agent, did not induce tolerance over 
this short time period; prolonged administration uas 
limited by the development of host antibodies to OKT3. A 
second protocol was initiated to assess whether the 
immunogenicity to OKT3 caul d be reduced by concomi tant 
administration of low dose steroids and azathioprine. 
Host antibody formation was reduced and most patients 
could be treated for thirty days. The results of this 
randomized study are not yet conclusive but do offer 
promi se that the prophyl acti c use of OKT3 may be 
worthwhile in renal allograft transplantation to reduce 
renal rejection and improve graft survival. 
The present study was directed to evaluating the 
potential of OKT3 in reversing acute renal allograft 
rejection that had not responded to conventional treatment 
wi th hi gh dose steroi ds and anti -thymocyte/lymphocyte 
gl obul in. The study attests to the effi cacy of the OKT3 
regimen described here in combating acute rejection and in 
maintaining renal function when other therapies have 
failed, and it also supplies a clinical alternative when 
other therapies may be contraindicated for reasons such as 
sensitivity to anti-thymocyte globulin, intercurrent 
infection or severe diabetes mellitus. Reversal of the 
acute rejecti on epi sode in 70 percent of patients, after 
the failure of conventional therapy, led to an actuarial 
kidney graft survival of 52 percent at 6 months. The 
several reports of 12-month graft survi val rates of more 
than 80 percent refer to rates for all i ncl uded patients 
receiving kidney transplants, many of whom either do not 
experience acute rejection or respond readily to 
conventional therapy, and do not bear compari son with the 
data reported here for patients experiencing acute 
rejection that is resistant to conventional therapy (Kahan 
et. al., 1985; Najarian et. al., 1985; Canadian Transplant 
Group, 1983). 
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The fl u-l i ke symptoms accompanying OKT3 therapy were 
particularly marked on the first day and were much reduced 
thereafter, which is consistent with the view that they 
are a consequence of acute elimination of the T lymphocyte 
population which is opsonized by OKT3 antibody. 
Respi ratory symptoms progressed to severe pu1 monary edema 
in two patients with pre-existing fluid overload. Once 
thi s uncommon comp1 ication of a fi rst dose of OKT3 was 
traced to. pre-existing fluid overload that circumstance 
was avoi ded in the remai ni ng patients by monitori ng for 
gain in weight and by radiography of the chest beforehand. 
OKT3 is a monoclonal antibody and therefore virtually 
free of the variations in constitution, concentration and 
potency that hamper therapy with polyclonal antibodies 
derived from antisera. Three ~echanismsI probably 
additive, deserve consideration with respect to the 
therapeutic effects of OKT3; namely, blocking of T3 
function (Chang et. al., 1981), modulation of T3 
(Chatenoud et. al., 1982) (phenotypic reduction of T3 and 
antigen-receptor expression on the T lymphocyte surface 
caused by antibody) and cytoel imi nation of T lymphocytes 
(Miller et al., 1981; Colvin et. al., 1981). 
Cytoelimination is not likely to be the only mechanism 
because although monoclonal antibodies to other components 
of the human T lymphocyte surface wi 11 opsoni ze T 
lymphocytes and cause their rapid elimination by the 
reticuloendothelial system, as does OKT3, they do not 
substantially avert renal allograft rejection (Carpenter 
et. al., 1983; Takahashi et. al., 1983; Thurlow et. a1., 
1983). 
OKT3 monoclonal antibody provides a new and highly 
selective method of blocking T lymphocyte function and 
averting immunological rejection of a renal allograft; 
further studies will be needed to defi ne its optimal use 
in transplantation. 
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